Malignant mesothelioma

Internal Medicine Journal

Volumn 40, Issue 11, 2010, Pages 742-750

  Kao, S C H ^a,b   Reid, G ^b   Lee, K ^a   Vardy, J ^a   Clarke, S ^a,b   Van Zandwijk, N ^b  

^a Department of Microbiology and Infectious Diseases   (Australia)

^b Bernie Banton Centre   (Australia)

Author keywords

Asbestos; Diagnosis; Epidemiology; Malignant mesothelioma; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; ASBESTOS; BEVACIZUMAB; BNC 105P; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; ERLOTINIB; FOLIC ACID; GEFITINIB; GEMCITABINE; IMATINIB; NAVELBINE; PEMETREXED; PLATINUM DERIVATIVE; RALTITREXED; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG;

AUSTRALIA; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG MECHANISM; FEBRILE NEUTROPENIA; HUMAN; MALIGNANT MESOTHELIOMA; NAUSEA AND VOMITING; PERICARDIUM; PLEURECTOMY; PRIORITY JOURNAL; REVIEW; TUNICA VAGINALIS; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION;

ANIMALS; ASBESTOS; AUSTRALIA; ENVIRONMENTAL EXPOSURE; HUMANS; MESOTHELIOMA;

EID: 78649648142     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2010.02223.x     Document Type: Review

References (73)

1. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005; 366: 397-408.
2. Tossavainen A, Tokahashi K. Epidemiological trends for asbestos-related cancers. People and Work Research Reports. Helsinki 36. FIOH, 2000; 26-30.
3. Rudd K. Bernie Banton Foundation Launch, Asbestos Diseases Research Institute, Concord Hospital, Sydney. 2009. [cited 2010 Sep 20]. Available from URL:
4. Yang H, Testa JR, Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol 2008; 9: 147-57.
5. Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z et al. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA 2006; 103: 10397-402.
6. Shukla A, Gulumian M, Hei TK, Kamp D, Rahman Q, Mossman BT. Multiple roles of oxidants in the pathogenesis of asbestos-induced diseases. Free Radic Biol Med 2003; 34: 1117-29.
7. Musk AW, Dolin PJ, Armstrong BK, Ford JM, De Klerk NH, Hobbs MST. The incidence of malignant mesothelioma in Australia, 1947-1980. Med J Aust 1989; 150: 242-6.
8. Musk AW, De Klerk NH. Epidemiology of malignant mesothelioma in Australia. Lung Cancer 2004; 45S: S21-3.
9. Leigh J, Davidson P, Hendrie L, Berry D. Malignant mesothelioma in Australia, 1945-2000. Am J Ind Med 2002; 41: 188-201.
10. Tracey E, Alam N, Chen W, Bishop J. Cancer in New South Wales: Incidence, Mortality and Prevalence Report 2006. Sydney: Cancer Institute NSW; 2008.
11. Heads of Workplace Safety Authorities. Campaign Report: Demolition and asbestos removal in the construction industry. An Australian & New Zealand joint Compliance Campaign, 2007.
12. Artcraft Research. Final Report on Focus Groups among the General Public, and Tradespeople. Canberra (ACT): ACT Asbestos Task Force; 2005.
13. Hendrickx M. Naturally occurring asbestos in eastern Australia: a review of geological occurrence, disturbance and mesothelioma risk. Environ Geol 2009; 57: 909-26.
14. Reid A, Heyworth J, De Klerk N, Musk AW. The mortality of women exposed environmentally and domestically to blue asbestos at Wittenoom, Western Australia. Occup Environ Med 2008; 65: 743-9.
15. Reid A, Berry G, De Klerk N, Hansen J, Heyworth J, Ambrosini G et al. Age and sex differences in malignant mesothelioma after residential exposure to blue asbestos (crocidolite). Chest 2007; 131: 376-82.
16. Pass HI, Vogelzang H, Hahn S, Carbone M. Malignant pleural mesothelioma. Curr Probl Cancer 2004; 28: 93-174.
17. Joshi TK, Gupta RK. Asbestos-related morbidity in India. Int J Occup Environ Health 2003; 9: 249.
18. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. World Health Organisation Classification of Tumours. Pathology and genetics of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press, 2004.
19. Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, De Vuyst P et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010; 35: 479-95.
20. Segal A, Whitaker D, Henderson D, Shilkin K. Pathology of mesothelioma. In: Robinson BWS, Chahinian A, eds. Mesothelioma. London: Martin Dunitz Ltd; 2002; 143-84.
21. British Thoracic Society Standards of Care Committee. BTS statement on malignant mesothelioma in the UK, 2007. Thorax 2007; 62: 1-19.
22. Stahel RA, Weder W, Felip E. On behalf of the ESMO Guidelines Working Group. Malignant pleural mesothelioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19: 43-4.
23. Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev 2004; 1: CD002916.
24. Sugarbaker D, Jaklitsch M, Bueno R, Richards W, Lukanich J, Mentzer SJ et al. Prevention, early detection and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 2004; 128: 138-46.
25. Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008; 135: 620-5.
26. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol 2009; 27: 2081-90.
27. Hasani A, Alvarez JM, Wyatt JM, Bydders S, Millward M, Byrne M et al. Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia. J Thorac Oncol 2009; 4: 1010-16.
28. Yan TD, Boyer M, Tin MM, Wong D, Kennedy C, McLean J et al. Prognostic features of long-term survivors after surgical management of malignant pleural mesothelioma. Ann Thorac Surg 2009; 87: 1552-7.
29. Yan TD, Boyer M, Tin MM, Wong D, Kennedy C, McLean J et al. Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors. J Thorac Cardiovasc Surg 2009; 138: 619-24.
30. Alvarex JM, Hasani A, Segal A, Sterret G, Millward M, Nowak A et al. Bilateral thoracoscopy, mediastinoscopy and laparoscopy, in addition to CT, MRI and PET imaging, are essential to correctly stage and treat patients with mesothelioma prior to trimodality therapy. ANZ J Surg 2009; 79: 734-8.
31. Weder W, Stahel R, Bernhard J, Bodis S, Vogt P, Ballabeni P et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007; 18: 1196-202.
32. Flores RM, Krug LM, Rosenzweig KE, Venkatraman E, Vincent A, Heelan R et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol 2006; 1: 289-95.
33. Rea F, Marulli G, Bortolotti L, Breda C, Favaretto AG, Loreggian L et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): feasibility and results. Lung Cancer 2007; 57: 89-95.
34. Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009; 27: 3007-13.
35. Agarwal PP, Seely JM, Matzinger FR, MacRae RM, Peterson RA, Maziak DE et al. Pleural mesothelioma: sensitivity and incidence of needle track seeding after image-guided biopsy versus surgical biopsy. Radiology 2006; 241: 589-94.
36. Bydder S, Phillips M, Joseph DJ, Cameron F, Spry NA, DeMelker Y et al. A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer 2004; 91: 9-10.
37. O'Rourke N, Garcia JC, Paul J, Lawless C, McMenemin R, Hill J et al. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol 2007; 84: 18-22.
38. Boutin C, Rey F, Viallat J-R. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. Chest 1995; 108: 754-8.
39. Bissett D, Macbeth FR, Cram I. The role of palliative radiotherapy in malignant mesothelioma. Clin Oncol 1991; 3: 315-17.
40. Linden C, Mercke C, Albrechtsson U, Johansson L, Ewers SB. Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a nonrandomized phase II study. Eur Respir J 1996; 9: 2565-72.
41. Rice DC, Stevens CW, Correa AM, Vaporciyan AA, Tsao A, Forster KM et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 2007; 84: 1685-93.
42. Miles EF, Larrier NA, Kelsey CR, Hubbs JL, Ma J, Yoo S et al. Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience. Int J Radiat Oncol Biol Phys 2008; 71: 1143-50.
43. Krayenbuehl J, Oertel S, Davis JB, Ciernik IF. Combined photon and electron three-dimensional conformal versus intensity-modulated radiotherapy with integrated boost for adjuvant treatment of malignant pleural mesothelioma after pleuropneumonectomy. Int J Radiat Oncol Biol Phys 2007; 69: 1593-9.
44. Allen AM, Czerminska M, Jänne PA, Sugarbaker DJ, Bueno R, Harris JR et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 2006; 65: 640-5.
45. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-44.
46. Hollen PJ, Gralla RJ, Liepa AM, Symanowski JT, Rusthoven JJ. Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso. Support Care Cancer 2006; 14: 11-21.
47. Symanowski JT, Rusthoven J, Nguyen B, Ruffie P, Moro-Sibilot D, Dabouis G et al. Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed + cisplatin vs. cisplatin in malignant pleural mesothelioma. Proc Am Soc Clin Oncol 2003; 22: abstr 2602.
48. Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 2008; 3: 756-63.
49. Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G et al. Phase II Study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006; 24: 1443-8.
50. Joshua AM, Burge ME, McNeil CM, Hui R, Boyer R, Abraham R. An Australian expereience of pemetrexed in malignant mesothelioma (MM). J Clin Oncol 2004; 22: 7285.
51. Sorensen JB, Frank H, Palshof T. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer 2008; 99: 44-50.
52. Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002; 87: 491-6.
53. Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CMB, Lowry E et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008; 371: 1685-94.
54. Van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23: 6881-9.
55. Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S et al. Phase III Trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008; 26: 1698-704.
56. Stebbing J, Powles T, McPherson K, Shamash J, Wells P, Sheaff MT et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 2009; 63: 94-7.
57. Nowak AK, Millward MJ, Francis R, Van Der Schaaf A, Musk AW, Byrne MJ. Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM). J Clin Oncol 2008; 26: abstr 8063.
58. Pavlakis N, Abraham R, Harvie R, Brock C, Bell D, Boyle F et al. Thalidomide alone or in combination with cisplatin/gemcitabine in malignant pleural mesothelioma (MM): interim results from two parallel non randomized phase II studies. Lung Cancer 2003; 41: S11.
59. Desai J, Wong S, Chong G, Bibby D, Leske A, Kremmidiotis G et al. Phase I, pharmacokinetic, and pharmacodynamic evaluation of BNC105P, a novel anticancer agent that is both a vascular disrupting agent (VDA) and an inhibitor of cancer cell proliferation. J Clin Oncol 2009; 27: abstr e14512.
60. Hawley R, Monk A, Wilshire J. The Mesothelioma Journey: Developing Strategies to Meet the Needs of People with Mesothelioma, Their Family Carers and Health Professionals Involved in Their Care. Sydney (NSW): Research Centre for Adaptation in Health and Illness; 2004.
61. Nowak AK, Stockler MR, Byrne MJ. Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module. J Clin Oncol 2004; 22: 3172-80.
62. Currow DC, Smith J, Abernethy AP. Does palliative home oxygen improve dysponea? A consecutive cohort study. Palliat Med 2009; 23: 309-16.
63. Ahmedzai S, Clayson H. Palliative care for mesothelioma. In: O'Byrne K, Valerie R, eds. Malignant Pleural Mesothelioma. Oxford: Oxford University Press; 2006; 412-18.
64. Robinson BWS, Creaney J, Lake R, Nowak A, Musk AW, De Klerk N et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362: 1612-16.
65. Park EK, Sandrini A, Yates DH, Creaney J, Robinson BW, Thomas PS et al. Soluble mesothelin-related protein in an asbestos exposed population. The Dust Diseases Board cohort study. Am J Respir Crit Care Med 2008; 178: 832-7.
66. Lopez-Rios F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostc factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 2006; 66: 2970-9.
67. Karrison T, Kindler HL, Gandara DR, Lu C, Guterz TL, Nichols K et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM). J Clin Oncol 2007; 25: 391S.
68. Millward M, Parnis F, Byrne M, Powell A, Dunleavey R, Lynch K et al. Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma. Proc Am Soc Clin Oncol 2003; 22: abstr 912.
69. Mathy A, Baas P, Dalesio O, Van Zandwijk N. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 2005; 50: 83-6.
70. Govindan R, Kratzke RA, Herndon JE, Niehans GA, Vollmer R, Watson D et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005; 11: 2300-4.
71. Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB et al. Phase II study of erlotinib in patients wtih malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2007; 25: 2406-13.
72. Hassan R, Broaddus VC, Wilson S, Liewehr DJ, Zhang J. Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts. Clin Cancer Res 2007; 13: 7166-71.
73. Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J et al. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun 2007; 7: 20.